1. Scrip
  2. >>Business

1Q Earnings Preview: What To Expect From US, EU Big Hitters

 
• By Scrip Team

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

Bernstein analysts expect Eli Lilly & Co. and several other big pharma companies that report earnings in US dollars to get a boost from the continued strengthening of the US dollar, creating a foreign exchange headwind after recent quarters when exchange rates hurt pharma revenues. Bernstein's Tim Anderson expects the company to report $0.88 in earnings per share (EPS) and $5bn in first quarter revenue, including a boost from recent sales growth for diabetes starJardiance (empagliflozin), which Lilly recently said it would test as a treatment for heart failure. Consensus estimates are for $4.8bn in revenue and EPS of $0.85. Investors will look for early sales figures from new products, including the recently approved Taltz (ixekizumab) for psoriasis (Also see "FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx " - Scrip, 23 March, 2016.).

As for future growth, expect analysts to derive new insights from Lilly executives about the company's most anticipated clinical data set – Phase III results for the Alzheimer's disease therapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Scrip

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By Mandy Jackson

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.